The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms
Abstract
BACKGROUND: Telavancin is an investigational, rapidly bactericidal lipoglycopeptide with a multifunctional mechanism of action. METHODS: We conducted 2 parallel, randomized, double-blind, active-control, phase 3 studies with a prespecified pooled analysis design. Patients aged > or = 18 years who had complicated skin and skin-structure infections caused by suspected or confirmed gram-positive organisms were randomized to receive either telavancin (10 mg/kg intravenously every 24 h) or vancomycin (1 g intravenously every 12 h). RESULTS: A total of 1867 patients were randomized and received > or = 1 dose of study medication. In the clinically evaluable population, at 7-14 days after receipt of the last antibiotic dose, success was achieved in 88% and 87% of patients who received telavancin and vancomycin, respectively (95% confidence interval for the difference, -2.1 to 4.6). Methicillin-resistant Staphylococcus aureus was isolated at baseline from samples from 579 clinically evaluable patients. Among these patients with methicillin-resistant S. aureus infection, cure rates were 91% among patients who received telavancin and 86% among patients who received vancomycin (95% confidence interval for the difference, -1.1 to 9.3). Microbiologic eradication among patients infected with methicillin-resistant S. aureus was 90% in the telavancin treatment group and 85% in the vancomycin treatment group (95% confidence interval for the difference, -0.9 to 9.8). Therapy was discontinued because of adverse events in 8% and 6% of patients who received telavancin and vancomycin, respectively. Except for mild taste disturbance, nausea, vomiting, and serum creatinine concentration elevation in the telavancin treatment group and pruritus in the vancomycin treatment group, adverse events were similar between groups with regard to type and severity. CONCLUSIONS: Telavancin given once daily is at least as effective as vancomycin for the treatment of patients with complicated skin and skin-structure infections, including those infected with methicillin-resistant S. aureus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department
Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., & Talan, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055356 · Cited by 2,285
The Changing Epidemiology of Staphylococcus aureus?
Chambers, H. F. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010204 · Cited by 1,495
Herold, B. C. (1998) · JAMA · doi:10.1001/jama.279.8.593 · Cited by 1,412
Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat
Grundmann, H., Aires-de-Sousa, M., Boyce, J., & Tiemersma, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68853-3 · Cited by 1,101
King, M. D., Humphrey, B. J., Wang, Y. F., Kourbatova, E. V., Ray, S. M., & Blumberg, H. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00005 · Cited by 776
A Clone of Methicillin-Resistant Staphylococcus aureus among Professional Football Players
Kazakova, S. V., Hageman, J. C., Matava, M., Srinivasan, A., Phelan, L., Garfinkel, B., Boo, T., McAllister, S., Anderson, J., Jensen, B., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042859 · Cited by 741
Seybold, U., Kourbatova, E. V., Johnson, J. G., Halvosa, S. J., Wang, Y. F., King, M. D., Ray, S. M., & Blumberg, H. M. (2006) · Clinical Infectious Diseases · doi:10.1086/499815 · Cited by 695
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
(1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.282.12.1123 · Cited by 574
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Self-citationBad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Self-citationNatural Products as Platforms To Overcome Antibiotic Resistance
Rossiter, S. E., Fletcher, M. H., & Wuest, W. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00283 · Cited by 622
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Gould, I. M., David, M. Z., Esposito, S., Garau, J., Lina, G., Mazzei, T., & Peters, G. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.028 · Cited by 294
Svetitsky, S., Leibovici, L., & Paul, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-09 · Cited by 275
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Antimicrobial Activity and Resistance: Influencing Factors
Li, J., Xie, S., Ahmed, S., Wang, F., Gu, Y., Zhang, C., Chai, X., Wu, Y., Cai, J., & Cheng, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00364 · Cited by 266
Important new therapies for methicillin-resistant Staphylococcus aureus
Bassetti, M., Carnelutti, A., Castaldo, N., & Peghin, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1675637 · Cited by 21
Metadata
- Authors
- Stryjewski, M. E., Graham, D. R., Wilson, S. E., O’Riordan, W., Young, D., Lentnek, A., Ross, D. P., Fowler, V. G., Hopkins, A., Friedland, H. D., Barriere, S. L., Kitt, M. M., Corey, G. R., & Study, O. B. O. T. A. O. T. I. C. S. A. S. I.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06
- Volume
- 46
- Issue
- 11
- Pages
- 1683-1693
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2126237265
- Cited by
- 289
- References
- 25
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.